The discovery of the HER2 receptor and advent of the HER2-directed monoclonal antibody (mAb) trastuzumab resulted in improved patient survival and has radically modified the natural history of HER2-positive breast cancer [3]. This evidence concerns the gene ERBB2 and breast carcinoma.